Home › Langerhans-Cell Histiocytosis › NCT05915208

Histiocytic Disorder Follow-up Study

Who can join

Ages 0 to 89 · All sexes

Inclusion Criteria:

* diagnosis of histiocytic disorder at any age

  1. Langerhans cell histiocytosis,
  2. Erdheim-Chester disease,
  3. Rosai-Dorfman disease,
  4. Xanthogranuloma,
  5. Mixed histiocytosis
  6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)
  7. Hemophagocytic lymphohistiocytosis

Exclusion Criteria:

* None

About the study

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders

Sponsor: University of Alabama at Birmingham · Participants: 6,000 · Started: Sep 1, 2022

Contact the study team

• Gaurav Goyal, MD · Phone: 1-866-438-1640

Official record on ClinicalTrials.gov — NCT05915208

Locations in the U.S.

Conditions

• Langerhans-Cell Histiocytosis
• Erdheim-Chester Disease
• Sinus Histiocytosis
• Second Primary Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.